Author

Robin Bechhofer

Observed names: R Bechhofer, R. Bechhofer

Institution: University of Wisconsin–Madison

Observed institutions: Roche (Switzerland), National Institutes of Health, Loyola University Medical Center, University of Wisconsin System, University of Wisconsin–Madison, Loyola University Chicago, UW Health University Hospital, University of Wisconsin Health, National Cancer Institute, Loyola Medicine

OpenAlex ID: A5073727127

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1988 · P M Sondel, P C Kohler, et al. · PubMed · 157

Repetitive Weekly Cycles of Recombinant Human Interleukin-2: Responses of Renal Carcinoma With Acceptable Toxicity1

1988 · J. A. Sosman, P. C. Kohler, et al. · JNCI Journal of the National Cancer Institute · 136

Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin

1988 · J. A. Sosman, P. C. Kohler, et al. · JNCI Journal of the National Cancer Institute · 109

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

1988 · J A Hank, P C Kohler, et al. · PubMed · 80

Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.

1997 · M R Albertini, J A Hank, et al. · PubMed · 68

Monitoring a clinical trial conducted under the food and drug administration regulations allowing a waiver of prospective informed consent: The diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trial

2001 · Roger J. Lewis, Donald A. Berry, et al. · Annals of Emergency Medicine · 40

Phase 1 Clinical Trial of Recombinant Interleukin-2: A Comparison of Bolus and Continuous Intravenous Infusion

1989 · Peter C. Kohler, Jacquelyn A. Hank, et al. · Cancer Investigation · 33

the influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2

1990 · Mark R. Albertini, Jeffrey A. Sosman, et al. · Cancer · 32

PDF

A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.

1993 · J H Schiller, J Hank, et al. · PubMed · 29

Serum CD25 Levels During Interleukin-2 Therapy

1992 · Mark P. Bogner, Stephan D. Voss, et al. · Journal of Immunotherapy · 24

Reports to Independent Data Monitoring Committees: An Appeal for Clarity, Completeness, and Comprehensibility

2017 · Kevin A. Buhr, Matthew Downs, et al. · Therapeutic Innovation & Regulatory Science · 23

Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.

1989 · D Goldstein, J A Sosman, et al. · PubMed · 23

The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.

1988 · N S Rosenthal, J A Hank, et al. · PubMed · 23

Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2.

1990 · J A Hank, J A Sosman, et al. · PubMed · 22

Prolonged Interleukin-2 (IL-2) Treatment Can Augment Immune Activation Without Enhancing Antitumor Activity in Renal Cell Carcinom

1991 · Jeff A. Sosman, Jacquelyn A. Hank, et al. · Cancer Investigation · 19

Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.

1995 · J A Hank, M Albertini, et al. · PubMed · 17

A Pilot Phase II Trial of Continuous-Infusion Interleukin-2 Followed by Lymphokine-Activated Killer Cell Therapy and Bolus-Infusion Interleukin-2 in Renal Cancer

1993 · Carlo Gambacorti-Passerini, Jacquelyn A. Hank, et al. · Journal of Immunotherapy · 11

Phase 1 clinical evaluation of recombinant interleukin-2.

1987 · P C Kohler, J A Hank, et al. · PubMed · 7

The QRS Interval Predicts Mortality and Re-Hospitalization in Patients Hospitalized with Worsening Heart Failure and Systolic Dysfunction

2007 · Norman C. Wang, Faiez Zannad, et al. · Journal of Cardiac Failure

Regional Comparison of Baseline Therapy in Patients Hospitalized for Acute Heart Failure with Systolic Dysfunction

2007 · Norman C. Wang, Marvin A. Konstam, et al. · Journal of Cardiac Failure

Regional Differences in Baseline Characteristics and Outcomes in Patients Hospitalized with Worsening Heart Failure and Systolic Dysfunction

2007 · Faiez Zannad, Norman C. Wang, et al. · Journal of Cardiac Failure

Works count: 21

Citation count: 853

H-index: 16

I10-index: 17